CpG-Stat3 siRNA treatment modifies balance between CD8 and Treg cells in AML mice. (A) Percentages of CD3⁺CD8⁺ T cells in the spleen (upper panel) and in the bone marrow (lower panel) of mice treated with CpG-Stat3 siRNA compared with untreated and CpG-Luc siRNA–treated groups assessed by flow cytometry. Mice were treated as described in Figure 2, and spleens and bone marrows were collected and analyzed by using flow cytometry. (B-C) Representative contour plots and bar graphs showing (B) percentages of activated CD8⁺CD69⁺ T cells or (C) CD4⁺FoxP3⁺ Tregs in spleens of AML-bearing mice under the same experimental conditions. Flow cytometric analysis after (B) extracellular or (C) intracellular staining for the indicated markers by using specific antibodies. Shown are means ± SD (n = 6). Statistically significant differences were indicated by asterisks: ***P < .001; **P < .01; *P < .05.